These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 11094920)

  • 21. A multi-centre, double-blind trial of tizanidine, a new antispastic agent, in spasticity associated with hemiplegia.
    Bes A; Eyssette M; Pierrot-Deseilligny E; Rohmer F; Warter JM
    Curr Med Res Opin; 1988; 10(10):709-18. PubMed ID: 3286129
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An approach to switching patients from baclofen to tizanidine.
    Brenner R; Hyman N; Knobler R; O'Brien M; Stephan T
    Hosp Med; 1998 Oct; 59(10):778-82. PubMed ID: 9850294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tizanidine as treatment of spasticity in patients with hemiplegia caused by a CVA or brain injury].
    Weynants L; Van Laere M
    Acta Belg Med Phys; 1990; 13(1):19-22. PubMed ID: 2336897
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacokinetics and pharmacodynamics of tizanidine.
    Roberts RC; Part NJ; Pokorny R; Muir C; Leslie GC; Emre M
    Neurology; 1994 Nov; 44(11 Suppl 9):S29-31. PubMed ID: 7970008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Spasticity: revisiting the role and the individual value of several pharmacological treatments.
    Lapeyre E; Kuks JB; Meijler WJ
    NeuroRehabilitation; 2010; 27(2):193-200. PubMed ID: 20871149
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Summary of combined clinical analysis of controlled clinical trials with tizanidine.
    Wallace JD
    Neurology; 1994 Nov; 44(11 Suppl 9):S60-8; discussion S68-9. PubMed ID: 7970013
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness comparison of tizanidine and baclofen in the management of spasticity.
    Rushton DN; Lloyd AC; Anderson PM
    Pharmacoeconomics; 2002; 20(12):827-37. PubMed ID: 12236804
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Symptomatic bradycardia probably due to tizanidine hydrochloride in a chronic hemodialysis patient.
    Kitabata Y; Orita H; Kamimura M; Shiizaki K; Narukawa N; Abe T; Kobata H; Akizawa T
    Ther Apher Dial; 2005 Feb; 9(1):74-7. PubMed ID: 15828911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modified release tizanidine: a review.
    Hutchinson DR
    J Int Med Res; 1989; 17(6):565-73. PubMed ID: 2697626
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of spasticity].
    Autti-Rämö I
    Duodecim; 1999; 115(8):877-85. PubMed ID: 11859520
    [No Abstract]   [Full Text] [Related]  

  • 31. [The use of sirdalud in painful muscle tonic syndromes].
    Damulin IV
    Ter Arkh; 1997; 69(10):68-72. PubMed ID: 9471796
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modified release tizanidine in the treatment of spasticity.
    Chantraine A; Van Ouwenaller C
    J Int Med Res; 1988; 16(6):459-65. PubMed ID: 3234596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tizanidine and electrophysiologic analysis of spinal control mechanisms in humans with spasticity.
    Delwaide PJ; Pennisi G
    Neurology; 1994 Nov; 44(11 Suppl 9):S21-7; discussion S27-8. PubMed ID: 7970007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tizanidine--initial pharmacokinetic studies in patients with spasticity.
    Heazlewood V; Symoniw P; Maruff P; Eadie MJ
    Eur J Clin Pharmacol; 1983; 25(1):65-7. PubMed ID: 6617726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Medical treatment of spasticity].
    Rode G; Maupas E; Luaute J; Courtois-Jacquin S; Boisson D
    Neurochirurgie; 2003 May; 49(2-3 Pt 2):247-55. PubMed ID: 12746699
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nightly sublingual tizanidine HCl in multiple sclerosis: clinical efficacy and safety.
    Vakhapova V; Auriel E; Karni A
    Clin Neuropharmacol; 2010 May; 33(3):151-4. PubMed ID: 20502134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Electrophysiological analysis of the mode of action of muscle relaxants in spasticity.
    Delwaide PJ
    Ann Neurol; 1985 Jan; 17(1):90-5. PubMed ID: 3985591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-spasticity medications.
    Al-Shahrani AM
    Saudi Med J; 2003 Jan; 24(1):19-22. PubMed ID: 12590267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis.
    Nance PW; Sheremata WA; Lynch SG; Vollmer T; Hudson S; Francis GS; O'Connor P; Cohen JA; Schapiro RT; Whitham R; Mass MK; Lindsey JW; Shellenberger K
    Arch Neurol; 1997 Jun; 54(6):731-6. PubMed ID: 9193208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Comparative effectiveness of different muscle relaxants in the rehabilitation of post-stroke patients with spasticity].
    Lipták J
    Ideggyogy Sz; 2013 Nov; 66(11-12):429. PubMed ID: 24555245
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.